The People-First Liver Charter

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-06-05 DOI:10.1038/s41591-025-03759-8

Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Silvana Pannain, Paul N. Brennan, Melina I. Manolas, Peter Jepsen, Carla Treloar, Anish K. Arora, Philippa C. Matthews, Camila A. Picchio, Trenton M. White, Jason Grebely, Juan Vaz, Hannes Hagström, Kenneth H. Rabin, Scott Isaacs, Rogério T. Ribeiro, Michael Roden, Michael Betel, José Willemse, Luis Antonio Díaz, Alina M. Allen, Naim Alkhouri, Jörn M. Schattenberg, Dídac Mauricio, Mary E. Rinella, Elisa Pose, Emmanuel A. Tsochatzis, Michael Ninburg, Kenneth Cusi, William Alazawi, Ajay Duseja, Gema Frühbeck, Holly Lofton, Priya Jaisinghani, Fasiha Kanwal, Gamal Shiha, Shira Zelber-Sagi, Larry Holden, Marcela Villota-Rivas

引用次数: 0

Abstract

Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins with the language used to name and describe them.

Abstract Image

查看原文本刊更多论文

以人为本的肝脏宪章

要减少肝病患者所遭受的耻辱和歧视，就需要重新思考如何看待诊断、疾病、病因和环境——这一转变始于用于命名和描述它们的语言。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.